District 6 Dinner Meeting: February 11

I would like to invite you to an upcoming Amgen Speaker Program for EVENITY¢ç (romosozumab-aqqg).

Please join us for an educational presentation on the importance of identifying patients with postmenopausal osteoporosis at high risk for fracture, determining their degree of risk, and criteria for the use of anabolic therapy as an appropriate initial therapy option.2 With a unique dual effect that both builds bone and, to a lesser extent, slows bone loss, EVENITY¢ç has been shown to build bone rapidly in 12 months and reduce the risk of new vertebral fractures.1

Please RSVP via phone or email: (870) 351-5270 or lnorwood@amgen.com